Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) updated its targeted alpha Radio-DARPin pipeline. Phase 1/2a dosing is ongoing for MP0712 (DLL3; 212Pb) in a US multicenter study with initial data expected in coming months and fuller safety/efficacy in 2027. FIH imaging for MP0726 (MSLN; planned) starts H2 2026; two INDs and a new target nomination are planned for 2027/2H 2026.
How this was made
The 30-second read
Why it matters
The company provides a concrete execution update (MP0712 dosing ongoing) plus forward-looking milestone timing (initial data in months; comprehensive dataset in 2027; MP0726 imaging in H2 2026; two INDs in 2027). This can affect near-term expectations and positioning ahead of first clinical readouts.
Market read
A pipeline execution update that can move expectations into the next clinical-data window, but lacks new efficacy/safety results in this release.
What to watch
Enrollment pace across five open centers and cohort dose-level completion could shift the “within the next months” data window; also, compassionate-care/early-access work (MP0714) is not the primary US program and may not translate into near-term valuation.
Background
Molecular Partners is advancing targeted alpha Radio-DARPin therapeutics, using isotope-agnostic DARPin vectors to pair with different alpha payloads.
Ticker impact
Molecular Partners says MP0712 dosing is ongoing in the US Phase 1/2a study, with initial data expected within months and fuller data in 2027.
Likely modest positive bias as investors price progress toward first clinical data, with volatility around any subsequent enrollment/early-data updates.
The release is a primary pipeline update (ongoing dosing, timing for initial/comprehensive data) rather than a new efficacy datapoint; impact should be incremental but tradable into upcoming readouts.
Market effects
Reinforces investor narrative that alpha-emitting, isotope-agnostic targeting platforms can accelerate multiple programs (DLL3, MSLN) and theranostic pairings.
Limited direct regional read-through; primarily US clinical execution with Swiss/US company operations.
Highlights ongoing global radiopharmaceutical development and isotope supply chain activity (e.g., 225Ac) that can influence sentiment across the radiopharma ecosystem.
Counterpoint
Because the release provides no new safety/efficacy data—only dosing status and future timelines—the stock reaction may fade until actual clinical readouts arrive.
Key entities
- companyMolecular Partners AG
Clinical-stage biotech developing DARPin therapeutics, including alpha Radio-DARPin candidates MP0712 and MP0726.
- programMP0712
DLL3-targeted Radio-DARPin carrying 212Pb; dosing ongoing in US Phase 1/2a with initial data expected within months.
- programMP0726
MSLN-targeted Radio-DARPin; first-in-human imaging planned for H2 2026.
- partnerOrano Med
Co-development partner for MP0712 (212Pb-based targeted alpha therapy).
